COYA Stock Forecast & Price Target

Coya Therapeutics Inc. has demonstrated significant advancements in its clinical execution, exemplified by a notable increase in collaboration revenue from $3.6 million to $7.9 million, primarily driven by the IND acceptance for COYA 302 in ALS and the initiation of patient dosing in the ALSTARS trial. The company's research has yielded promising results, revealing statistically significant increases in regulatory T cell functionality and numbers, which may support a Phase 2a program in frontotemporal dementia (FTD). Additionally, the publication of peer-reviewed findings linking impaired Treg function in FTD patients to the biological rationale for COYA 302 enhances the company's credibility and prospects in the neuroinflammatory therapeutic space.

Coya Therapeutics Inc is facing significant financial challenges, as evidenced by a net loss increase from -$14.9 million in 2024 to -$21.2 million in 2025, alongside an increased loss per share from ($0.98) to ($1.27). The company's reliance on intellectual property protection is precarious, with concerns that key patents could fail, potentially exposing Coya to costly legal disputes and infringement suits. Furthermore, the possibility that emerging treatment methods could make Coya's therapies non-competitive adds to the uncertainty surrounding the company’s future viability in the biotechnology sector.